Advertisement

Topics

ACR Roundup: JAK Safety Shown Across Multiple Trials

10:52 EST 10 Nov 2017 | SCRIP

Low cardiovascular risk was shown in trials presented at the ACR/ARHP annual meeting for Pfizer's, Lilly's and AbbVie's JAK inhibitors...

      

Related Stories

 

Original Article: ACR Roundup: JAK Safety Shown Across Multiple Trials

NEXT ARTICLE

More From BioPortfolio on "ACR Roundup: JAK Safety Shown Across Multiple Trials"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...

Pfizer
Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...

Lilly
Eli Lilly and Company was founded in 1876, and is now the 9th largest pharmaceutical company based an annual sales which were just under $20bn in 2009. Orginally from the USA, Lilly now operates in over 50 countries with just under 40,000 employees. Appr...